Trial Profile
An observational real world study to evaluate the malignancy risk in rheumatoid arthritis patients treated with Abatacept and that of Biologic Disease-modifying Antirheumatic Drug (bDMARD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab; Anakinra; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Rituximab; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 07 Dec 2018 Results published in the Rheumatology
- 02 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism